NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier.
The blood-brain barrier (BBB) regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like stroke and epilepsy.
The company’s approach involves precisely targeting the pathways responsible for BBB formation, with the aim to restore lost functionality to the neurovasculature. NeuVasQ plans to further develop this targeted approach.
The company’s current focus is to identify the most promising indications for clinical trials, focusing on a range of neurodegenerative disorders and acute neurological disorders. As part of these exploratory studies, NeuVasQ will also consider various therapeutic modalities, including gene and mRNA therapy.
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …